Core Insights - Corvus Pharmaceuticals reported positive interim results from the Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing earlier and deeper responses compared to earlier cohorts, with a significant reduction in itch as early as day 8 [1][4][3] - The company is advancing its clinical trials, with ongoing enrollment in Phase 1 trial extension cohort 4 and plans to initiate a Phase 2 trial before the end of the year [1][3] - Corvus is also enrolling patients in a Phase 3 registrational clinical trial of soquelitinib for relapsed/refractory peripheral T cell lymphoma (PTCL) [1][6] Clinical Development - Soquelitinib demonstrated a mean reduction in Eczema Area and Severity Index (EASI) score of 64.8% in cohort 3 at 28 days, compared to 54.6% for cohorts 1 and 2 combined [4] - The Phase 1 trial showed a favorable safety profile, with no dose-limiting toxicities reported [4] - A separate Phase 1b/2 trial in China is planned to further explore soquelitinib's efficacy in atopic dermatitis with a 12-week treatment period [3][4] Financial Performance - As of June 30, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $74.4 million, an increase from $52.0 million at the end of 2024 [9] - The company reported a net loss of $8.0 million for the second quarter of 2025, compared to a net loss of $4.3 million for the same period in 2024 [11] - Research and development expenses for the second quarter of 2025 were $7.9 million, up from $4.1 million in the same period in 2024, primarily due to increased clinical trial costs [10] Strategic Collaborations - Corvus is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) for a Phase 2 clinical trial in autoimmune lymphoproliferative syndrome (ALPS) [5] - The company has partnered with Angel Pharmaceuticals to develop and commercialize its clinical-stage candidates in China [23] Upcoming Events - A conference call and webcast is scheduled for August 7, 2025, to discuss the business update and second-quarter financial results [12][13]

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-3 ...

Soquelitinib作用机制和潜力 - Soquelitinib 是一种 First-in-Class 的免疫调节剂，在癌症和免疫疾病领域具有广泛的机会[4] - Soquelitinib 通过阻断 ITK 信号通路，能够调节 Th1/Th2/Th17 细胞的平衡，从而影响多种炎症细胞因子的产生[11, 29] - ITK 抑制剂具有广阔的治疗潜力，包括肿瘤免疫治疗、免疫疾病、肺部炎症、胃肠道疾病、纤维化疾病和皮肤病等[7] - Corvus 团队的领导成员曾参与 rituximab 和 ibrutinib 的开发[5] Soquelitinib 在 Atopic Dermatitis (AD) 临床试验中的结果 - 在 AD 的 Phase 1 临床试验中，Soquelitinib 在 Cohorts 1 和 2 中显示出 54.6% 的 EASI 平均降低[42] - Cohort 3 的 EASI 平均降低为 64.8%[42] - Cohort 3 中，50% 的患者在第 28 天实现了 PP-NRS 评分至少降低 4 分，表明瘙痒症状得到显著改善[53] - 在接受 Soquelitinib 治疗的患者中，75% 在 EASI 50 中有所改善，83% 在 EASI 50 中有所改善[42] - 29% 的患者在 EASI 75 中有所改善，50% 的患者在 EASI 75 中有所改善[42] - 4% 的患者在 EASI 90 中有所改善，8% 的患者在 EASI 90 中有所改善[42] - 21% 的患者 IGA 0 或 1 中有所改善，25% 的患者 IGA 0 或 1 中有所改善[42] Soquelitinib 的安全性 - 在 Cohorts 1、2 和 3 中，Soquelitinib 表现出良好的安全性和耐受性，未发生严重不良事件[49] - 38.9% 的 Soquelitinib 治疗患者出现不良反应，而安慰剂组为 25%[49] AD 市场机会 - G7 国家有大约 30 million 的 AD 患者，其中约 3 million 为中重度患者，但只有 10% 接受了先进疗法治疗[34] - AD 市场预计到 2030 年将达到 280 亿美元[34]

Core Viewpoint - Corvus Pharmaceuticals has announced the approval of an IND application for a Phase 1b/2 clinical trial of soquelitinib in China, targeting patients with moderate-to-severe atopic dermatitis, which is expected to begin patient enrollment in Q3 2025 [1][3]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new immunotherapy approach for various cancers and immune diseases [6][7]. - Angel Pharmaceuticals, co-founded by Corvus, is responsible for developing, manufacturing, and commercializing soquelitinib in greater China, with Corvus holding approximately 49.7% ownership [2][5]. Clinical Trial Details - The Phase 1b/2 trial will study a 12-week treatment period with a 400 mg once-daily dose of soquelitinib, building on previous clinical data [3][6]. - The trial will be randomized, double-blinded, and placebo-controlled, enrolling patients with moderate-to-severe atopic dermatitis [3][6]. - The Phase 1b trial will include two cohorts, each with 24 patients, testing different dosing regimens [6]. Market Context - Atopic dermatitis is a growing concern globally, with increasing use of biologics and systemic therapies, particularly in China [3].

Core Insights - Corvus Pharmaceuticals announced preclinical data on soquelitinib's potential to treat systemic sclerosis, to be presented at the EULAR 2025 Congress [1] - The presentation was selected as a top 10 abstract by the Emerging EULAR Network, indicating significant interest in the research [1] - The company is focusing on developing soquelitinib for various conditions, including peripheral T cell lymphoma and atopic dermatitis, while considering future trials for systemic sclerosis [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in ITK inhibition for cancer and immune diseases [3] - The lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK [3] - The company is also developing other clinical-stage candidates for various cancer indications [3]

Core Insights - Corvus Pharmaceuticals announced interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing cohort 3 (200 mg BID) had earlier and deeper responses compared to cohorts 1 and 2 [1][2][3] - The trial demonstrated a statistically significant improvement in the Eczema Area and Severity Index (EASI) score at day 28, with cohort 3 showing a mean reduction of 64.8% compared to 34.4% for placebo [1][3] - An extension cohort study has been initiated to explore the same dose of soquelitinib for a longer treatment period of 8 weeks [1][14] Efficacy Data - All three cohorts showed statistically significant separation from placebo at day 28, with cohort 3 achieving clinically meaningful reduction in itch as early as day 8 [1][4] - The mean reduction in EASI score for cohort 3 was 64.8%, while cohorts 1 and 2 combined showed a reduction of 54.6% [3][4] - At day 28, no placebo patients achieved IGA 0 or 1 or EASI 75, while cohort 3 had one patient achieving EASI 75 with an 89% reduction in EASI score [7][11] Safety Profile - As of May 28, 2025, soquelitinib was well tolerated with no new safety signals, and only one treatment-related adverse event of grade 1 nausea reported [12] - Grade 1/2 adverse events were observed in 38.9% of patients receiving soquelitinib compared to 25% in the placebo group [12] Biomarker Studies - Reductions in serum cytokines (IL-5, IL-9, IL-17, IL-31, IL-33, TSLP, and TARC) were observed, with cohort 3 showing greater reductions compared to cohorts 1 and 2 [13] - Relationships between cytokine reductions and improvements in EASI scores were noted, with no such relationships in the placebo group [13] Future Directions - The company is optimistic about the potential of soquelitinib as a safe and effective treatment for atopic dermatitis and other immune diseases, with further improvements expected from the extension cohort [2][14] - The extension cohort will enroll 24 patients randomized 1:1 between active and placebo, with an 8-week treatment period [14]

Core Viewpoint - Corvus Pharmaceuticals, Inc. is actively engaging with investors at the 2025 Jefferies Global Healthcare Conference, highlighting its innovative approach in immunotherapy and its lead product candidate, soquelitinib [1][3]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy strategy for various cancers and immune diseases [3]. - The company's lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is developing additional clinical-stage candidates targeting a range of cancer indications [3]. Event Details - The leadership team will present a corporate overview and conduct one-on-one meetings with investors at the conference in New York on June 5, 2025, from 9:20 to 9:50 am ET [1]. - A live webcast of the presentation will be available for 90 days post-event, accessible through the investor relations section of the Corvus website [2].

Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference call and we ...

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage bi ...

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, which will be presented at the Society for Investigative Dermatology 2025 Annual Meeting [1][2] - The company will discuss this data during its first quarter 2025 business update conference call scheduled for May 8, 2025 [1][3] Presentation Details - The presentation titled "Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action" will be delivered by Dr. Albert S. Chiou [2] - The poster presentation is set for May 8, 2025, from 4:30 – 6:00 pm PT, while the oral presentation will occur on May 10, 2025, from 9:50 – 10:00 am PT [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK, with other candidates in development for different cancer indications [4]